TrialJournal of neurology, neurosurgery, and psychiatry2022

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.

Michel Dominique Ferrari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.